Adding a cholesterol shot to a statin opened narrowed brain arteries after stroke

If you or someone you love has had a stroke from clogged arteries in the brain, here is good news. Adding a cholesterol-lowering injection to a high-intensity statin opened up narrowed brain arteries more than the statin alone. Most people on the add-on also reached a very low LDL cholesterol level.

That matters because this type of stroke tends to come back, even with intensive treatment. Now there is a promising extra step you can ask your neurologist about.

How the study worked

Researchers randomly assigned 62 people with a stroke caused by narrowed arteries inside the skull to one of two plans for 6 months: a high-intensity statin alone, or the same statin plus an injection of alirocumab every 2 weeks (75 mg). The average age was 66, and 77% of the group were men. Detailed MRI scans of the artery walls measured the narrowing, and the study appeared Sept. 9, 2026 in the Journal of the American Heart Association. It was a small trial and patients knew which treatment they got, so larger studies will show how this plays out over the long term, including on repeat strokes.

What they found

The arteries opened up more with the add-on. After 6 months, the narrowing in the alirocumab group had shrunk by a median of 7.1%. In the statin-only group, it was about the same, changing by −1.2%. Once the researchers adjusted for where everyone started, the gap between the two groups came to about 9 percentage points, or exactly 8.9 percentage points.

The cholesterol numbers were striking:

• With the add-on: 85% of people got their LDL cholesterol below 55 mg/dL.
• With the statin alone: 13% got there.

New strokes during the study happened in 5% of the add-on group and 13% of the statin-only group. Both groups also saw a drop in plaque enhancement volume, a scan sign of active plaque, and the two drops were similar.

Safety looked good too. No serious adverse events were reported in either group.

What is PCSK9, and why does LDL matter here?

LDL is the cholesterol that feeds the fatty plaque inside artery walls. Statins lower it, and for many people that is enough. A PCSK9 inhibitor, like alirocumab, is an injection that brings LDL down much further than a statin alone.

In this trial, the goal was an LDL below 55 mg/dL. That is a very low number, and the add-on helped most people reach it. The artery results suggest that getting LDL that low may help plaque shrink, not just stop growing.

Why this is a relief

Narrowed brain arteries are hard to treat. Many people with this problem are already taking strong medicine and still worry about another stroke. This trial shows that a second cholesterol medicine can add something real: more opening in the arteries and far more people reaching a very low LDL.

It also gives you a simple, concrete topic for your next appointment. You do not need to know the science. You just need to know your number.

What you can do today

Find your most recent LDL result. It may be on a lab printout, in your patient portal, or on your pharmacy or Medicare paperwork. Write it on a sticky note next to the LDL goal your neurologist has set for you. If you do not know your goal, write that down as a question. Bring the note to your next neurology visit and ask, “Am I reaching my LDL target, and what are my options if I am not?”